David Zaccardelli, Verona Pharma CEO

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

Verona Phar­ma has se­cured up to $650 mil­lion to aid the po­ten­tial launch of its COPD can­di­date en­sifen­trine.

Un­der new

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.